Cary Street Partners Asset Management’s iShares iBonds Dec 2023 Term Treasury ETF IBTD Stock Holding History

Cary Street Partners Asset Management’s Portfolio IBTD Stock Details IBTD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,147	Closed	-$748K	–	205
2023 Q3	$748K	Sell	30,147 -13,592	-31%	-$337K	0.14%	117
2023 Q2	$1.09M	Sell	43,739 -2,329	-5%	-$57.7K	0.2%	98
2023 Q1	$1.14M	Buy	46,068 +43,449	+1,659%	+$1.07M	0.22%	91
2022 Q4	$64.7K	Hold	2,619	–	–	0.01%	244
2022 Q3	$65K	Buy	+2,619	New	+$65.1K	0.02%	212

Other funds holding IBTD

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cary Street Partners Asset Management's IBTD Position: Q4 2023 in Review

Cary Street Partners Asset Management sold out of iShares iBonds Dec 2023 Term Treasury ETF (IBTD) in Q4 2023, closing a stake of 30,147 shares — an estimated $748K sold.

Cary Street Partners Asset Management first reported a position in IBTD in Q3 2022 and held it in 5 quarters. The position peaked at $1.14M in Q1 2023. 3 funds tracked by Wall St. Rank hold IBTD as of Q4 2023.

Cary Street Partners Asset Management reported no remaining iShares iBonds Dec 2023 Term Treasury ETF position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Asset Management sold 30,147 iShares iBonds Dec 2023 Term Treasury ETF shares in Q4 2023, an estimated $748K.
Cary Street Partners Asset Management first reported a position in iShares iBonds Dec 2023 Term Treasury ETF in Q3 2022 and held it in 5 quarters.
Cary Street Partners Asset Management's iShares iBonds Dec 2023 Term Treasury ETF position peaked at $1.14M in Q1 2023.
3 funds tracked by Wall St. Rank held iShares iBonds Dec 2023 Term Treasury ETF as of Q4 2023.

Based on Cary Street Partners Asset Management's 13F filing for Q4 2023, filed 5 Feb 2024.